Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 12/20 | 0.65 |
| ▸ | HTR2C | P28335 | 3/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.65 |
| ▸ | HTR1A | P08908 | 2/20 | 0.65 |
| ▸ | DRD2 | P14416 | 2/20 | 0.65 |
| ▸ | HRH1 | P35367 | 2/20 | 0.65 |
| ▸ | DRD3 | P35462 | 2/20 | 0.65 |
| ▸ | HTR2B | P41595 | 2/20 | 0.65 |
| ▸ | HTR6 | P50406 | 2/20 | 0.65 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.65 |
| ▸ | DRD4 | P21917 | 1/20 | 0.65 |
| ▸ | DRD5 | P21918 | 1/20 | 0.65 |
| ▸ | HTR1D | P28221 | 1/20 | 0.65 |
| ▸ | HTR1E | P28566 | 1/20 | 0.65 |
| ▸ | HTR7 | P34969 | 1/20 | 0.65 |
| ▸ | HTR5A | P47898 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30321010 | 1.00 | HTR2A (0.65) | HTR2AHTR2CADRB1HTR1ADRD2 | |
| SCHEMBL25545392 | 0.90 | HTR2A (0.69) | HTR2AHTR2CADRB1HTR1ADRD2 | |
| SCHEMBL30321037 | 0.90 | HTR2A (0.69) | HTR2AHTR2CADRB1HTR1ADRD2 | |
| SCHEMBL25545417 | 0.89 | KDM4E (0.69) | HTR2AHTR2CADRB1HTR1ADRD2 | |
| SCHEMBL30321017 | 0.89 | KDM4E (0.69) | HTR2AHTR2CADRB1HTR1ADRD2 | |
| SCHEMBL25545430 | 0.87 | HTR2A (0.70) | HTR2AHTR2CADRB1HTR1ADRD2 | |
| Lysergide SCHEMBL28081619 | 0.82 | HTR2A (0.91) | HTR2AHTR2CADRB1HTR1ADRD2 | |
| SCHEMBL30886877 | 0.82 | HTR2A (0.80) | HTR2AHTR2CADRB1HTR1ADRD2 | |
| SCHEMBL2469887 | 0.82 | HTR2A (0.80) | HTR2AHTR2CADRB1HTR1ADRD2 | |
| SCHEMBL30298949 | 0.81 | HTR2A (0.66) | HTR2AHTR2CADRB1HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787806-B2 | Ergoline analogues | Beckley Psytech Limited (GB) | 2023-10-17 | — | — | US | disclosed |
| US-11787806-B2 | Ergoline analogues | Beckley Psytech Limited (GB) | 2023-10-17 | — | — | US | disclosed |
| US-11697651-B2 | Ergoline analogues | Beckley Psytech Limited (GB) | 2023-07-11 | — | — | US | disclosed |
| US-11697651-B2 | Ergoline analogues | Beckley Psytech Limited (GB) | 2023-07-11 | — | — | US | disclosed |
| US-20230167112-A1 | ERGOLINE ANALOGUES | Beckley Psytech Limited (GB) | 2023-06-01 | — | — | US | disclosed |
| US-20230167112-A1 | ERGOLINE ANALOGUES | Beckley Psytech Limited (GB) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11697651-B2 | Ergoline analogues | ERG, ADRA2C, ADRB2 | HTR2A 62/4885HTR2C 116/4885ADRB1 12/4885 |
| US-11787806-B2 | Ergoline analogues | ERG, ADRA2C, ADRB2 | HTR2A 62/4885HTR2C 116/4885ADRB1 12/4885 |
| US-20230167112-A1 | ERGOLINE ANALOGUES | ERG, ADRA2C, ADRB2 | HTR2A 62/4885HTR2C 116/4885ADRB1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.